Results 221 to 230 of about 26,394,857 (313)

Valorization of bark extracts from Cerrado and Amazon species: phenolic characterization, antioxidant capacity, and photoprotective potential for circular bioeconomy applications

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Tree bark remains an underexploited source of high‐value‐added phenolic compounds with potential circular bioeconomy applications. This work characterized bark extracts from two species of distinct Brazilian biomes, Stryphnodendron adstringens (Cerrado) and Myrcia eximia (Amazon), obtained with three solvents (ethanol, methanol and acetone ...
Mário Sérgio Lorenço   +7 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Open-Source Multimodal Imaging and Clinical Data Set for Uveal Melanoma. [PDF]

open access: yesOphthalmol Sci
Ganesh SS   +5 more
europepmc   +1 more source

Ceftriaxone‐associated immune haemolytic anaemia: A patient‐level systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Ceftriaxone can cause acute haemolysis. Its clinical presentation, risk factors, and outcomes remain incompletely characterized. We conducted a systematic review of published cases with patient‐level data, following international guidelines and with registration in PROSPERO (CRD420261338709). Reports were identified through three bibliographic
Sonja Miotti   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy